|Bid||0.00 x 2900|
|Ask||0.00 x 1200|
|Day's range||140.23 - 156.32|
|52-week range||76.59 - 331.68|
|Beta (5Y monthly)||1.59|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Dr. Ben Weston, Milwaukee COVID-19 Emergency Operations Center Medical Director, talks about the process of approving the COVID-19 vaccine for children and the global fight against COVID-19.
Shares of Novavax (NASDAQ: NVAX) were jumping 6.1% higher as of 10:48 a.m. EDT on Wednesday after rising as much as 15.8% earlier in the morning. The nice gain came following the company's announcement that it has filed for authorization of its COVID-19 vaccine NVX-CoV2373 to the United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). Novavax's U.K. submission is an important milestone for the company.
Shares of Novavax (NASDAQ: NVAX) have been extremely volatile as the market tries to value the company's COVID-19 vaccine. In January of last year, the company's stock was valued at $4 a share. The stock zoomed higher when COVID-19 hit, the tiny company introduced its vaccine candidate, and saw early success in clinical trials.